Evaluation of treatments for bone metastases
Official title: Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort
Run by UMC Utrecht · NCT02356497 · Data updated 2026-11-12
This study is testing how well standard treatments work for people with bone metastases to help improve their care and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 2500 (estimated) |
| Sponsor | UMC Utrecht Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Utrecht, Utrecht) |
| Status | Recruiting |
| Started | June 2013 |
| Main results expected | December 2035 |
| Study ends | December 2035 |
| Registry record updated | March 19, 2026 |
| Trial ID | NCT02356497 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults over 18 years with histologically confirmed malignancy and metastatic bone disease undergoing radiotherapy.
✕Probably not a fit
Patients with a life expectancy of less than one week or those who are mentally incompetent may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The PRESENT cohort is designed to evaluate patients with bone metastases receiving standard care while collecting clinical and patient-reported outcomes. Patients provide informed consent to participate in the cohort and may be randomly selected for future randomized controlled trials (RCTs) within the cohort. This approach allows for the identification of factors influencing treatment response and the development of survival models. The study aims to improve treatment selection and quality of life for patients suffering from painful bone metastases.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment strategies and better quality of life for patients with bone metastases.
How similar studies have gone: Other studies have shown success with similar cohort designs, indicating potential for meaningful advancements in treatment evaluation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Histologic proof of malignancy; * Radiographic or histologic proof of metastatic bone disease; * Undergoing radiotherapy; * Age \> 18 years; * Informed consent - at least - for use of routinely collected clinical data. Exclusion Criteria: * Mentally incompetent patients; * Life expectancy \< 1 week indicated by the treating physician.
Where it's running
-
University Medical Center Utrecht
Utrecht, Utrecht, Netherlands Recruiting
Study contacts
- Principal investigator: Helena M. Verkooijen, MD, PhD — UMC Utrecht
- Study coordinator: Roxanne Gal, PhD
- Email: r.gal@umcutrecht.nl
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Prophylactic Radiotherapy to Prevent Bone Complications in Metastatic Cancers
This study tests whether giving early radiotherapy to high-risk bone metastases, in addition to standard care, can reduce bone-related problems in adults with metastatic solid cancers.
-
Focused high-dose SBRT for spinal tumors
This program will try focused high-dose SBRT for adults with spinal metastases to track side effects and local tumor control during routine care.
-
Registry for people with symptomatic bone metastases
This registry collects health information from adults with symptomatic bone metastases who need treatment for painful or unstable bone lesions to learn more about outcomes and care.
-
One-visit, simulation-free single-dose radiation for painful bone metastases
This trial tests whether adults with one or two painful bone metastases can get pain-relieving radiation in a single visit using a simulation-free planning approach.
-
Dual Energy CT to Delineate Tumors and Organs at Risk in Radiotherapy
This study tests whether dual-energy CT can delineate tumors and nearby critical tissues as well as MRI for patients needing radiotherapy.
-
Early radiotherapy versus observation for high‑risk painless or minimally painful bone metastases
This will test whether giving preventive radiotherapy to people with high‑risk but painless or minimally painful bone metastases can reduce future bone complications, hospital stays, and symptoms compared with observation and usual treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.